Companies › Eli Lilly · Global Markets & Policy
Eli Lilly and Company
- NYSE: LLY
US drugmaker whose products include the diabetes and obesity treatments Mounjaro and Zepbound.
Eli Lilly quarterly results and earnings history →
Insider trades (Form 4)
Last 120 days: open-market sales $18.8M, purchases $0. All Eli Lilly insider transactions →
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Patrik Jonsson EVP & President, LLY Int'l | Open-market sale 10b5-1 plan | 6,500 | $1175.10 | $7.6M | Form 4 ↗ |
| Aug 10, 2026 | Donald A Zakrowski SVP, Finance, & CAO | Open-market sale 10b5-1 plan | 2,000 | $1185.01 | $2.4M | Form 4 ↗ |
| Aug 7, 2026 | Anat Hakim EVP, GC & Secretary | Open-market sale 10b5-1 plan indirect | 5,000 | $1190.00 | $6.0M | Form 4 ↗ |
| Jun 10, 2026 | Ilya Yuffa EVP&Pres, LLY USA&Global Capab | Open-market sale 10b5-1 plan | 2,500 | $1150.77 | $2.9M | Form 4 ↗ |
Key financials
| Metric | FY to Dec 2022 | FY to Dec 2023 | FY to Dec 2024 | FY to Dec 2025 |
|---|---|---|---|---|
| Revenue | $28.5B | $34.1B | $45.0B | $65.2B |
| Net income | $6.2B | $5.2B | $10.6B | $20.6B |
| Diluted EPS | $6.90 | $5.80 | $11.71 | $22.95 |
Fiscal years, from annual reports (10-K / 20-F). Source: SEC EDGAR (XBRL company facts), retrieved 2026-10-03. Verify figures against the original filings.
Recent filings
- 2026-08-05 · 10-Q
- 2026-08-05 · 8-K — Results of operations
- 2026-05-20 · 8-K — Other events
- 2026-05-07 · 8-K — Shareholder vote results
- 2026-04-30 · 10-Q
- 2026-04-30 · 8-K — Results of operations
- 2026-03-20 · DEF 14A
- 2026-02-12 · 10-K
Source: SEC EDGAR, retrieved 2026-10-03. Filing types explained: 8-K, 10-Q, 10-K, 20-F / 6-K.
Not investment advice. This page lists official filings and our reports for reference. SignalStack does not rate securities or recommend buying or selling anything.